Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Lexaria Bioscience Corp. LEXX

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Devoting Research, Product Development to Make Drug Substances More Effective

Lexaria Bioscience Corp. (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in the approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many obstacles that may … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry

Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands

Lexaria Bioscience Corp. (NASDAQ: LEXX) is expected to begin dosing for the NIC-H22-1 human study this summer. “NIC-H22-1, a pharmacokinetic randomized, double-blinded, cross-over study involving 36 human participants, will compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands

In its most recent oral nicotine study, Lexaria established that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controlsLexaria hopes to evidence in its upcoming human … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Update on its Patented DehydraTECH(TM) Technology, Including the Approval of New Patent

Lexaria received its 25th patent – and the first patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugsThe company is seeking IND approval from the FDA and has commenced its human HYPER-H21-4 study for hypertension … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH

Lexaria just received another patent for DehydraTECH(TM): this time for the enhanced delivery of antiviral drugsThis becomes the company’s 25th patent granted worldwide and the 10th granted in the U.S.It adds to the company’s growing patent portfolio, which also consists … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform

Lexaria Bioscience Corp. (NASDAQ: LEXX) is aware of the need to continuously improve its understanding of the capabilities and potential applications of its patented DehydraTECH(TM) drug delivery technology. This informs its long-held commitment to its applied research and development (“R&D”) … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices

Lexaria expects to begin dosing this summer as part of a human nicotine study, NIC-H22-1, to compare DehydraTECH-nicotine pouch performance to that of existing leading brands such as ON! and ZynSo far, the company’s animal studies have evidenced that the … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. According to the update, Lexaria has received … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4, is the most comprehensive study … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment